PPGLs

Paraganglioma and pheochromocytoma (PPGLs) are rare neuroendocrine tumors originating from neural crest cells and composed of chromaffin and sustentacular cells. PPGLs share histomorphological features and are classified based on their location: extra-adrenal for paraganglioma and adrenal for pheochromocytoma. 

The "Great Masquerader"

Pheochromocytoma is often called the "Great Masquerader" (or Great Mimicker) because its symptoms—like panic attacks, headaches, and racing heart—closely resemble many other conditions, often leading to a long and difficult search for the correct diagnosis. Pathology evaluation plays an irreplaceable role in diagnosing pheochromocytoma/paraganglioma.

Pathologists face the unique challenge that there are no absolute histological features to define a pheochromocytoma as "malignant" other than the presence of distant metastases. 

All pheochromocytomas are currently considered to carry a lifelong risk of metastasis. Multiparameter scoring systems (PASS, GAPP, and COPPS) have been used to assess the risk of aggressive behavior in pheochromocytomas; however, they show high interobserver variability and inconsistent predictive value. Interpretation of these scoring systems is best guided by integration with clinical and molecular information.

According to the American Joint Committee on Cancer (AJCC), there are only three well-recognized clinical predictors of metastasis: 
1) primary tumor size, 
2) primary tumor location (adrenal vs. extra-adrenal), and 
3) germline mutations of SDHB

Genetic "Red Flags"

Up to 40% of these tumors harbor germline mutations (e.g., SDHB, VHL, RET). Pathological loss of SDHB expression, as assessed by immunohistochemistry, is a strong indicator of a potential hereditary syndrome and a higher metastatic risk. Identifying SDHB loss in pathology is the standard "first step" to determine which patients require urgent, comprehensive germline genetic testing, and closer follow-up.